Description: Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Myceliophthora thermophila, named C1. The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs (such as virus like particles (VLPs) and antigens), monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. Additionally, and more recently, Dyadic is also beginning to explore the use of its C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of Adeno-associated viral vectors (AAV) and certain metabolites. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies in development and manufacture of biopharmaceuticals. In particular, as the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic drugs to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers and, hopefully, improve access and cost to patients and the healthcare system, but most importantly save lives.
Home Page: www.dyadic.com
DYAI Technical Analysis
140 Intracoastal Pointe Drive
Jupiter,
FL
33477-5094
United States
Phone:
561 743 8333
Officers
| Name | Title |
|---|---|
| Mr. Mark A. Emalfarb | Founder, CEO, Pres & Director |
| Ms. Ping Wang Rawson CPA, M.B.A. | Chief Financial Officer |
| Mr. Joseph P. Hazelton | Chief Bus. Officer |
| Dr. Ronen Tchelet Ph.D. | VP of Research & Bus. Devel. |
| Ms. Ana Gómez Rodriguez | Sec. of the Board |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Life Sciences Tools & Services |
| Forward PE: | 11.5473 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.8763 |
| Price-to-Sales TTM: | 14.1681 |
| IPO Date: | 2004-11-05 |
| Fiscal Year End: | December |
| Full Time Employees: | 7 |